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A B S T R A C T
This is a protocol for a Cochrane Review (Prognosis). The objectives are as follows:
Primary objective
The primary objective of this review is to determine which technique (test) for assessing MGMTmethylation status best predicts overall
survival in people diagnosed with glioblastoma who are treated with temozolomide. We will consider each MGMT test as a separate
prognostic factor.
See Table 2 for the review question in population, index prognostic factor, comparator prognostic factor(s), outcome, timing, and
setting (PICOTS) format.
Secondary objective
We will undertake a full integrated economic review to identify economic evaluations in relation to the different methods of assessing
MGMTmethylation status effect on overall survival. Furthermore, we will develop a simple cost-effectiveness decision model exploring
the cost-effectiveness of alternative approaches to assessing MGMT methylation status.
Investigation of sources of heterogeneity
If we identify a sufficient number of studies for inclusion, we will examine for each technique/test whether any of the following features
is best associated with overall survival.
• Promoter region/ 5’-C-phosphate-G-3’ (CpG)s analysed (or the antibody used in the case of immunohistochemistry)
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• Cut-off used (where relevant)
• Type of tumour sample (FFPE or frozen)
We will also investigate the effect of population characteristics including the following.
• Age
• Extent of tumour resection
• Karnofsky performance status
• IDH status
• Recurrent versus first diagnosis
We are assuming constant HRs. To confirm the validity of this assumption we will investigate length of follow-up as a source of
heterogeneity. If studies have started follow-up for overall survival from different timepoints, we will also investigate this as a source of
heterogeneity.
B A C K G R O U N D
Description of the health condition and context
Glioblastoma is an aggressive form of brain cancer. Approximately
five of every 100 people with glioblastoma survives for five years
past diagnosis (Ostrom 2014). Glioblastomas that have a particu-
lar modification to their DNA (called methylation) in a particular
region (theO6-methylguanine-DNAmethyltransferase (MGMT)
promoter) respond better to treatment with chemotherapy using
a drug called temozolomide. Although we know that modification
of this DNA region is important, we don’t know the best way to
measure it. In this Cochrane Review we aim to assess which way
of measuring methylation of the MGMT promoter best predicts
survival when people with glioblastoma are treated with temozolo-
mide.
Gliomas are a group of brain tumours that share some features
with glial cells, which are the cells that support and insulate neu-
rons. The World Health Organization (WHO) divides gliomas
into astrocytic, oligodendroglial, and ependymal tumours, and
other rarer subtypes depending on the type of glial cell the tumour
shares features with (Louis 2016). Glioblastoma is themost malig-
nant (aggressive) type of astrocytic tumour (Louis 2016), and the
most common primary brain tumour among adults. Age-adjusted
incidence of primary (isocitrate dehydrogenase (IDH)-wild type)
glioblastoma (ICD-O-3 morphology codes 9440 to 9442, WHO
grade IV) ranges from 0.59 to 3.69 per 100,000 people (Ostrom
2014). IDH-wildtype glioblastomas increase in incidence with
age, peaking in the 74 to 84-year old age group (Ostrom 2014).
These glioblastomas are associated with poor prognosis, with a
five-year relative survival of approximately 5% (Ostrom 2014).
The median overall survival is 9.9 months for people treated with
surgery plus radiotherapy, and 15 months for people treated with
surgery plus radiotherapy plus chemotherapy (Louis 2016). For
peoplewith secondary (IDH-mutant) glioblastomas,median over-
all survival is 24 months for people treated with surgery plus ra-
diotherapy, and 31 months for people treated with surgery plus
radiotherapy plus chemotherapy (Louis 2016).
Most people presenting with neurological symptoms are referred
to their local neurosurgical multidisciplinary team following imag-
ing with computerized tomography (CT) and magnetic resonance
imaging (MRI) scans of the brain. If appropriate, the person pro-
ceeds to diagnostic biopsy or resection (surgical removal) of the tu-
mour to confirm a histopathological diagnosis. Once the diagnosis
has been confirmed, the decision ismade for subsequent treatment,
which can include radiotherapy and chemotherapy. For newly di-
agnosed glioblastoma, maximal surgical resection followed by ra-
diation therapy with concomitant and adjuvant temozolomide is
standard therapy (Stupp 2005). Temozolomide is a chemother-
apeutic, more specifically an alkylating agent, that causes DNA
damage. This DNA damage results in inhibition of DNA repli-
cation. Not all people respond to temozolomide therapy to the
same extent. There is evidence that people with newly diagnosed
glioblastomawho start treatmentwith radiation therapy and temo-
zolomide greater than six weeks after neurosurgery have worse
overall survival than people who start treatment within six weeks
(Sun 2015).
In the UK, it is estimated that on average just over 20 years of
life are lost per person with a brain tumour, the most of any form
of cancer (Burnet 2005). Olesen 2012 estimated the total annual
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costs of brain tumours in Europe to be EUR 5.2 billion, based
upon Purchasing Power Parity (PPP) rates for 2010.
Description of the prognostic factors
MGMT is a DNA repair enzyme in tumour cells that can repair
the damage caused by alkylating agents, such as temozolomide.
Methylation of MGMT in the tumour cell stops the repair en-
zyme working and the tumour cell can’t repair itself and therefore
the cancer cell then dies. If the MGMT in the tumour cell is un-
methylated, then the cancer cell can repair the damage caused by
temozolomide and therefore temozolomide is ineffective. Epige-
netic silencing of the MGMT gene by promoter methylation is
associated with longer overall survival in people with glioblastoma
receiving alkylating therapy in addition to radiotherapy (Esteller
2000; Hegi 2004; Hegi 2005). A retrospective analysis of a ran-
domized phase III trial found that treatment with temozolomide
and radiotherapy conferred a significant survival benefit versus ra-
diotherapy alone in people with MGMT promoter methylation
(median survival 21.7 months, 95% confidence interval (CI) 17.4
to 30.4 versus 15.3 months 95% CI 13.0 to 20.9, P = 0.007),
whereas a smaller difference in survival between treatment groups
was seen in people with unmethylated MGMT (median survival
12.7 months, 95% CI 11.6 to 14.4 versus 11.8 months 95% CI
9.7 to 14.1) (Hegi 2005).
It is thought that glioblastomas that have silenced the MGMT
gene are less capable of repairing the damage caused by temozolo-
mide, and thereforemore sensitive to alkylating therapy (Brandner
2015). However, MGMT methylation status does not always re-
flect gene expression, so the exact mechanism by which MGMT
promoter methylation improves response to alkylating therapy is
still unknown.
MGMT promoter methylation status testing is clearly important
in treatment decisions in elderly people, as treating tumours with
an unmethylated MGMT promoter with temozolomide is detri-
mental (when single agent temozolomide chemotherapy was com-
pared to radiotherapy) (Malmström 2012; Wick 2012). On the
basis of these findings professional bodies, such as the European
Association for Neuro-Oncology (EANO), recommend evalua-
tion of MGMT promoter methylation status in elderly people
(Weller 2017). The National Institute for Health and Care Excel-
lence (NICE) recommends that all high-grade gliomas are tested
for MGMT promoter methylation to inform prognosis and guide
treatment in their guideline on primary brain tumours and brain
metastases in adults (NICE 2018). Most non-elderly (aged under
65 years) people are treated with temozolomide chemotherapy ir-
respective of MGMT promoter status, possibly due to the lack of
alternative treatments (Hegi 2015). However, MGMT promoter
status is still a useful prognostic marker which may impact clinical
management, and may also be used for recruitment into clinical
trials for novel therapies.
There aremanyways of assessingmethylation status. These include
the following.
• Quantitative real time polymerase chain reaction (PCR) or
MethylLight methylation-specific quantitative PCR
• Methylation-specific PCR (MSP)
• Methylation specific sequencing, including pyrosequencing
• Bead array
• Methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA)
• PCR with high resolution melting (HRM)
• Co-amplification at lower denaturation temperature
(COLD)-PCR
• Digestion-based assays
We have briefly described these techniques in Table 1. In addition,
protein expression or enzymatic activity may be used as a proxy for
methylation status. However, internationally accepted consensus
about the most appropriate diagnostic method for MGMT pro-
moter status is lacking (Brandner 2015). MSP was used to assess
MGMT promoter status in the landmark study by Hegi 2005.
The choice of technique used to assess MGMT promoter status
in practice may depend on the amount and quality of the DNA
sample(s) (e.g. Formalin-Fixed Paraffin-Embedded (FFPE) versus
frozen tissue-derived DNA), the robustness and simplicity of the
method, the availability of equipment and reagents necessary for
each of the techniques, cost, and experience. In the last UK Na-
tional Quality Assessment (UKNEQAS) External Quality Assess-
ment report, of 18 UK laboratories 10 used pyrosequencing, five
MSP, two HRM, and one MS-MLPA. In addition, these tech-
niques can only investigate methylation status in specific regions
within the MGMT promoter (which may be different even when
the same technique is used), and the effect of methylation status
at different sites on prognosis is not well understood. In addi-
tion, some of the techniques quantify the amount of methylation
present, and there is no consensus regarding the cut-off for cate-
gorizing methylation status.
The result of each technique/test for MGMT status can be con-
sidered a separate prognostic factor for predicting overall survival
in people with glioblastoma treated with temozolomide.
Health outcomes
The health outcome of interest for this review is overall survival.
We are not limiting the period of follow-up. Glioblastomas are
associated with poor prognosis, so we anticipate that most studies
will assess overall survival within five years of diagnosis.
Why it is important to do this review
It is important to reach a consensus regarding which is the best
method for assessing MGMT methylation status based on the
prognostic value of each method in predicting overall survival in
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people with glioblastoma treated with temozolomide. The regions
of the promoter that need to be analysed and the most relevant
cut-offs for quantitative tests need to be established. Systematic re-
views have assessed the prognostic value of MGMT promoter sta-
tus assessed by a specific technique, for example by pyrosequenc-
ing (Zhao 2016), or MSP (Zhang 2013). However, no review has
determined which method is best correlated with prognosis (al-
though a review, Dullea 2016, aimed to do this but provided no
quantitative synthesis of the results, only a narrative overview).
In this Cochrane Review we will seek to determine which tech-
nique, assessing which regions, and (if relevant) which cut-off is
best associated with overall survival in people with glioblastoma
treated with temozolomide. We will consider each MGMT test
as a separate prognostic factor. We will extract or calculate (where
possible) hazard ratios (HRs) for those who test positive compared
to those who test negative. A test that is not better than flipping
a coin is expected to have a HR of one. The better the test can
distinguish between those with a good overall survival versus those
with poor overall survival, the further the HR value will be from
one.
By seeking to determine which technique, assessing which regions,
and (if relevant) which cut-off is best associated with overall sur-
vival in people with glioblastoma treated with temozolomide, this
review will partially answer the question “Do molecular subtyping
techniques improve treatment selection, prediction and prognos-
tication in people with brain and spinal cord tumours”, one of the
top 10 topics identified by the James Lind Alliance Neuro-On-
cology Priority Setting Partnership (JLA PSP 2018). The James
Lind Alliance is an organization that brings patients, carers, and
clinicians together to set research priorities. The National Cancer
Research Institute Brain Tumour Clinical Studies Group has also
identified this as an area for future research.
It is also important to consider the cost effectiveness of alternative
methods of assessing MGMT promoter methylation status. Each
method of assessment will incur costs, such as laboratory costs,
clinic costs, and subsequent treatment costs. The benefits of tar-
geting treatment may include greater survival and less exposure
to potentially toxic treatments, as well as potential cost-savings
from the avoidance of waste from the use of ineffective drugs. This
review will consider the costs alongside the consequences of the
prognostic tests to understand the value that they provide to the
healthcare system.
O B J E C T I V E S
Primary objective
The primary objective of this review is to determine which tech-
nique (test) for assessing MGMT methylation status best predicts
overall survival in people diagnosed with glioblastoma who are
treated with temozolomide. We will consider each MGMT test as
a separate prognostic factor.
See Table 2 for the review question in population, index prognos-
tic factor, comparator prognostic factor(s), outcome, timing, and
setting (PICOTS) format.
Secondary objective
We will undertake a full integrated economic review to identify
economic evaluations in relation to the differentmethods of assess-
ing MGMTmethylation status effect on overall survival. Further-
more, we will develop a simple cost-effectiveness decision model
exploring the cost-effectiveness of alternative approaches to assess-
ing MGMT methylation status.
Investigation of sources of heterogeneity
If we identify a sufficient number of studies for inclusion, we
will examine for each technique/test whether any of the following
features is best associated with overall survival.
• Promoter region/ 5’-C-phosphate-G-3’ (CpG)s analysed (or
the antibody used in the case of immunohistochemistry)
• Cut-off used (where relevant)
• Type of tumour sample (FFPE or frozen)
We will also investigate the effect of population characteristics
including the following.
• Age
• Extent of tumour resection
• Karnofsky performance status
• IDH status
• Recurrent versus first diagnosis
We are assuming constant HRs. To confirm the validity of this
assumption we will investigate length of follow-up as a source of
heterogeneity. If studies have started follow-up for overall survival
from different timepoints, we will also investigate this as a source
of heterogeneity.
M E T H O D S
Criteria for considering studies in this review
Types of studies
We will include longitudinal studies of adults with diagnosed
glioblastoma treated with temozolomide with/without radiation
therapy/surgery that have related MGMT status in tumour tissue
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assessed by one or more technique with overall survival. This in-
cludes the temozolomide treated arms of RCTs. We will also in-
clude nested case-control studies. We will exclude cohort studies
performed exclusively in people who have survived a particular
amount of time.
We will exclude case reports.
To be included, studiesmust have determinedMGMTstatus from
samples taken prior to the initiation of treatment. We will include
studies with any length of follow-up.
We will only include studies if HRs are reported or can be calcu-
lated from the data reported.
Types of studies for the economic component
We will include economic evaluations conducted alongside trials,
modelling studies, and cost analysis to inform the identification
of cost effectiveness outcomes.
Targeted participants
We will include studies of adults with diagnosed glioblas-
toma treated with temozolomide with/without radiation therapy/
surgery.
If studies included people with other forms of glioma (and we
cannot extract results for the population with glioblastoma), we
will include these if other forms of glioma make up less than 10%
of the population.
We will exclude studies performed exclusively in paediatric popu-
lations (under 18 years of age). We will include studies of partici-
pants with either first diagnosis or recurrent glioblastoma. Partic-
ipants in eligible studies could receive concomitant and adjuvant
therapies in addition to temozolomide (e.g. surgery or radiation
therapy, or both). If not all participants received temozolomide
(e.g. in the context of a RCT), we will include data on people who
did receive temozolomide if this is available.
Types of prognostic factors
We will include studies that assess MGMT promoter methylation
status in tumour tissue by one or more techniques.
We will treat each test for MGMT as a separate prognostic factor.
Eligible techniques will include MSP; quantitative real time PCR
or MethylLight methylation-specific quantitative PCR; methyla-
tion-specific sequencing, including pyrosequencing; bead array;
MS-MLPA; PCR with HRM; COLD-PCR; and digestion-based
assays.
We will include testing strategies that look at MGMT expression
(e.g. immunohistochemistry for protein expression, or tests look-
ing at messenger ribonucleic acid (mRNA) levels), or MGMT en-
zymatic activity.
Eligible techniques must be performed directly on tumour tissue.
We will exclude studies that assess MGMT promoter methylation
status from blood samples. We will only include molecular tech-
niques. We will exclude studies that infer MGMT methylation
status due to macroscopic morphological changes that can be de-
tected by, for example, imaging (i.e. MRI, CT, positron emission
tomography (PET)).
We will exclude studies if the method of determining MGMT
promoter methylation status is not reported, as this information
is essential for this review.
Types of outcome to be predicted
• Overall survival
Outcomes of the economic component
• Resources use, costs, cost effectiveness, and cost-utility of
different methods of assessing MGMT promoter methylation
status based on full economic review
• Relative efficiency of each method of testing for MGMT
promoter methylation status based on a decision model using the
outcomes from the review of effectiveness and from the full
integrated economic review
Search methods for identification of studies
Electronic searches
We will search the following databases:
• MEDLINE Ovid (from 1946 to current date)
• Embase Ovid (from 1980 to current date)
The MEDLINE search strategy is in Appendix 1. We will adapt
this for Embase.
We will search the BIOSIS Citation Index (from 1969 to current
date) using the search strategy in Appendix 2.
We will also search for studies available in PubMed that are not
available inMEDLINEusing the syntax ‘pubmednotmedline[sb]’.
There will be no restrictions based on language or date of publi-
cation.
Searching other resources
We will search Open Grey (www.opengrey.eu/) using the free text
terms from our MEDLINE search ((glioblastom* or GBM or
astrocytom* or gliosarcom*) AND (((methylguanin* or methyl
guanin* or alkylguanin* or alkyl guanin*)AND(methyltransferas*
or methyl transferas* or alkyltransferas* or alkyl transferas*)) or
AGT or MGMT or AGAT) AND (prognos* or predict* or mor-
tality or death* or surviv*)).
We will search for relevant material in dissertations and
theses using ProQuest Dissertations & Theses Global (
search.proquest.com/pqdtglobal/dissertations/), again using the
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same strategy as for Open Grey but limiting to all fields except
full text. We will also search the Networked Digital Library of
Theses and Dissertations ( search.ndltd.org/index.php) using the
same strategy as for Open Grey.
The Society of Neuro-Oncology (SNO), and its partner associa-
tions the EANO and the Japan Society of Neuro-Oncology, hold
meetings where relevant researchmay be presented.We will search
for abstracts from these meetings and other relevant conferences
via the Web of Science Conference Proceedings Citation Index
(CPCI-S) (from 1990 to current date). We will translate the BIO-
SIS search for CPCI-S as both databases are hosted on Web of
Science.
We will examine the reference lists of included studies, and of sys-
tematic reviews that have assessed the prognostic value of MGMT
promoter status overall (Binabaj 2018), or as assessed by a specific
technique; for example by pyrosequencing (Zhao 2016), or MSP
(Zhang 2013).
Search methods for the economic component
Wewill perform searches for economic evaluation studies inMED-
LINE and Embase from January 2015 to current date. In addition,
we will search the NHS Economic Evaluation Database (EED) up
to the end of December 2014, when the last records were added
to that database. The NHS EED was based on a comprehensive
search of bibliographic databases including MEDLINE and Em-
base, so searches ofMEDLINE andEmbase before 1 January 2015
are not required.Wewill also consider relevant grey literature (such
as health technology assessments, reports, and working papers) for
inclusion.
Data collection
We will use EPPI-Reviewer 4 to perform the review.
Selection of studies
Two review authors will independently screen titles and abstracts
of all identified search results. We will retrieve the full-text of
any article(s) that either review author deems relevant, or whose
relevance cannot be determined from the abstract. Two review
authors will then independently assess the full-text articles. We
will resolve any disagreements by consensus, or by consulting a
third review author if necessary. Articles excluded during full-text
assessment will be listed in a ’characteristics of excluded studies’
table. We will construct a preferred reporting items for systematic
reviews and meta-analyses (PRISMA) flow diagram to depict the
flow of information through the different phases of the review.
We will perform full data extraction, risk of bias assessment and
synthesis on studies that evaluatedMGMT promoter methylation
status of the same patients using two or more techniques, and will
perform more limited data extraction on studies that evaluated
MGMT promoter methylation status using a single technique.
Selection of studies for the economic component
We will include full economic evaluation studies in this review.
This includes evaluations alongside trials and model-based evalu-
ations and cost analysis.
Data extraction and management
Two review authors will independently perform data extraction.
We will resolve any disagreements by consensus, and will consult
a third review author if necessary.
For studies that evaluated MGMT promoter methylation status
of the same patients using at least two techniques, we will extract
data on the following items relevant to prognostic factor studies,
derived from the checklist for critical appraisal and data extraction
for systematic reviews of predictionmodelling studies (CHARMS)
(Moons 2014).
Study characteristics
• Author
• Year
• Country
• Length of follow-up
• Study dates
• Study design
Population characteristics
• Number of participants
• Population source and setting
• Timing of MGMT promoter methylation assessment
• Inclusion/exclusion criteria
• Tumour type
• Age
• Gender
• Karnofsky performance status
• Extent of resection
• Treatment regimen
• Length of time between neurosurgery and start of treatment
• IDH mutation status
• First diagnosis or recurrent disease
• Deaths during follow-up
• Prevalence of MGMT promoter methylation (by each
technique)
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Method(s) of MGMT promoter methylation assessment
• Technique
• Tumour sample type (i.e. FFPE or frozen tissue)
• Region/CpGs analysed (for PCR-based tests); antibody
used (for immunohistochemistry)
• Cut-off/threshold used to determine MGMT promoter
methylation status
• Method of determining threshold and whether it was
prespecified
Outcome assessment
• Timepoint from which overall survival is measured
Missing data
• Number of participants with any missing data
Association between MGMT methylation status and overall
survival
• We will extract unadjusted HRs and variances, with a HR
value less than one indicating favourable outcomes in people
with a methylated MGMT promoter. If HR values are not
directly reported, we will calculate these, where possible, using
the techniques described in Tierney 2007 and Parmar 1998.
• Adjusted HRs and variances (where reported), and factors
the result is adjusted for. We will extract these to confirm that
MGMT tests have added prognostic value in addition to easier
to measure prognostic factors such as age, gender, disease stage at
diagnosis, and comorbidity.
For studies that evaluated MGMT promoter status using a single
technique we will extract details on author, year, country, length
of follow-up, number of participants, tumour type, IDH muta-
tion status and technique used for MGMT promoter methylation
assessment.
In addition to the above, we will collect the following data from
the economic evaluation studies.
• Type of evaluations
• Sources of effectiveness data
• Cost data
• Sources of cost data
• Sources of outcome valuations
• Analytical approach
Assessment of risk of bias in included studies
We will assess risk of bias of studies that evaluated MGMT pro-
moter methylation status of the same patients using at least two
techniques.
The quality in prognosis studies (QUIPS) tool is designed to assess
risk of bias in prognostic factor studies (Hayden 2013). It assesses
bias across six domains: study participation, study attrition, prog-
nostic factor measurement, outcome measurement, study con-
founding, and statistical analysis and reporting. We will assess risk
of bias across QUIPS domains, although we have combined the
domains of study participation and study attrition into one do-
main (participant selection), we have added a domain on sub-
sequent treatment, we have renamed the study confounding do-
main to adjustment for other potential prognostic factors, and we
have limited the domain about statistical analysis and reporting
to selective reporting. We have replaced the prompting items and
considerations, which mainly assessed reporting, with signalling
questions to help us come to domain-level judgements. The do-
main modifications and signalling questions have been informed
by the CHARMS checklist (Moons 2014), a framework for assess-
ing internal validity of articles dealing with prognosis described
in Altman 2001, as well as ROBINS-I (risk of bias in non-ran-
domized studies of interventions) (Sterne 2016) and QUADAS-
2 (Whiting 2011). In addition, for each domain apart from selec-
tive reporting, we have added questions assessing the applicability
of the study as in QUADAS-2 (Whiting 2011) and PROBAST
(Wolff 2019).
We will judge risk of bias and concerns regarding applicability
as either high, low, or unclear. The tool is detailed in Appendix
3. Two review authors will independently perform assessments,
and will aim to reach a consensus judgement. We will resolve any
disagreements by consulting a third review author.
Assessment of risk of bias in studies included in the
economic component
Assessment of the quality of the economic evaluations that are
captured in this review will take place in two stages. The first stage
is assessing the quality of the clinical effectiveness evidence that
informs the evaluation. If the economic evaluationhas been carried
out alongside a single study, then we will use the bespoke tool
described in Appendix 3 for quality assessment. If the economic
evaluation is based on multiple sources, such as a modelling study,
then we will use the ROBIS (risk of bias in systematic reviews)
tool to assess the quality (Whiting 2016).
The second stage involves assessing the quality of the economic
component of the evaluation. We will use both the consoli-
dated health economic evaluation reporting standards (CHEERS)
(Husereau 2013) and the Evers checklist (Evers 2005) to assess the
quality of the economic evidence.
Assessment of heterogeneity
We will quantify heterogeneity across results of the studies using
an estimate of the between-study variance in logHRs and will por-
tray these using prediction intervals if we perform meta-analyses.
We will report between study variance (τ 2 ). In addition, we will
describe the extent of inconsistency in the findings using the I2
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statistic, which describes the percentage of variation across studies
that is due to heterogeneity rather than chance (Higgins 2002).
Assessment of reporting bias
For each meta-analysis that contains 10 or more studies, we will
examine the symmetry of funnel plots and test for asymmetry
using Debray’s-Funnel inverse variance test based onHRs (Debray
2018). Asymmetry may be an indicator of publication bias.
Data synthesis
Data synthesis and meta-analysis approaches
To assess the relative prognostic ability of the different techniques
wewill focus ondata fromdirect, within-study comparisons, where
the MGMT promoter methylation status of the same series of
people is evaluated in multiple ways and the results correlated
with overall survival. Full data extraction, risk of bias assessment,
and synthesis on studies will be undertaken only for this subset
of studies. The prognostic value of each test may be dependent
on other prognostic factors of overall survival, and these may have
been adjusted for. We will also aim to extract and meta-analyse
adjusted results, to confirm that the tests have added prognostic
value in addition to (easier to measure) prognostic factors such as
age, gender, disease stage at diagnosis, and comorbidity.
We also expect to identify studies that have evaluated MGMT
promoter using only one technique. We will present only brief
details of these studies. At a later date we may investigate these
studies further to supplement inferences from the comparative
studies. Specifically, there may be a possibility of comparing tech-
niques indirectly across studies. Indirect comparisons rely on the
assumption that the studies assessing each test for MGMT pro-
moter methylation are similar for all important characteristics, i.e.
that they have been conducted on similar populations that have
been given similar treatments (or that these factors are adjusted
for) and that the risk of bias is similar.
We will present the results from the full economic review as a nar-
rative analysis, describing the results of the economic evaluations
identified by the search. In addition to the narrative summary of
the economic evaluations, we will use both the clinical and eco-
nomic outcomes to inform a decision model to estimate the cost
effectiveness of assessing MGMT status in the management of
glioma.
Subgroup analysis and investigations of heterogeneity
Wewill investigate the potential sources of heterogeneity in the re-
sults for each method using subgroup analyses or meta-regression,
depending on the number of studies identified and the nature of
the source of heterogeneity.
If we identify a sufficient number of studies, we will examine for
each technique/test whether any of the following features is best
associated with overall survival.
• The promoter region/CpGs analysed (or the antibody used
in the case of immunohistochemistry)
• The cut-off used (where relevant)
• The type of tumour sample (FFPE or frozen).
We will also investigate the effect of population characteristics
including:
• Age
• Extent of tumour resection
• Karnofsky performance status
• IDH status
• Recurrent versus first diagnosis.
We will assume constant HRs. To test the validity of this assump-
tion, we will investigate length of follow-up as a source of hetero-
geneity. If studies have started follow-up for overall survival from
different timepoints, we will also investigate this as a source of
heterogeneity.
Sensitivity analyses
We plan to perform a sensitivity analysis restricting the analysis to
studies we judge to be at low or unclear risk of bias.
Decision model
We will create an economic model using outcomes from both the
clinical and economic evidence we identify. We will use the ex-
tracted data to populate a decision analyticmodel, whichwill assess
the cost-effectiveness of different methods of testing for MGMT
promoter methylation status in people with glioma. The effect of
the different methods of assessing MGMT promoter methylation
status (including not assessing for promoter methylation status
at all) will be compared in terms probability of effectiveness and
overall survival. This will be from a UK NHS perspective in a
population aged 65 years or over. The time horizon of the model
in terms of costs considered will be six weeks until the start of
temozolomide treatment and we will assess parameter uncertainty
using a sensitivity analysis.
Summary of findings
We will present the prognostic value of each test on overall sur-
vival in a ‘Summary of findings’ table. We will assess confidence
in each result by following the GRADE approach (Guyatt 2008).
Guidance on the use of GRADE for prognostic factor studies has
not yet been published, although adaptations have been proposed
(Huguet 2013). We will rate the overall strength of evidence as
either ‘high’, ‘moderate’, ‘low’ or ‘very low’. We will consider risk
of bias, indirectness, inconsistency, imprecision, and publication
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bias, which may lead to downgrading of the strength of the ev-
idence; and size of effect, which may lead to upgrading of the
strength of the evidence (see Appendix 4).
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A D D I T I O N A L T A B L E S
Table 1. Methods of determining methylation status
Test Brief description
MSP In MSP, DNA is extracted from tumour tissue and then treated with sodium bisulfite. Sodium
bisulfite causes changes in the sequence of unmethylated DNA, as it changes the DNA base
cytosine into uracil. Methylated DNA is protected and remains unchanged. Regions of DNA can
then be amplified using PCR in a manner that is dependent on whether the changed (containing
uracil) or original sequence (containing cytosine) is present
Quantitative real time PCR This technique is very similar toMSP, but there is ameasure of the amount of changed and original
DNA sequence
Methylation-specific sequencing In methylation-specific sequencing, DNA is again extracted from tumour tissue and treated with
sodium bisulfite, which changes unmethylated DNA. The DNA can then be sequenced to see if it
contains the changed or original sequence, i.e. whether it contains uracil in place of cytosine. There
are many ways of sequencing DNA, but one commonly used method is called pyrosequencing
Bead array In this technique DNA is again extracted from tumour tissue and treated with sodium bisulfite,
which changes unmethylated DNA. The DNA is then hybridized to sequences that are either
complementary to the original sequence or changed sequence. The hybridization produces a signal
which can be measured
MS-MLPA In MLPA the DNA is treated with an enzyme that cleaves unmethylated DNA at specific se-
quences, but methylated DNA is protected. PCR to amplify regions of DNA is then performed.
Amplification will only occur if the DNA was not cleaved
PCR with HRM This technique relies on the fact that the changes to DNA caused by sodium bisulfite (i.e. the
replacement of cytosine by uracil) lead to it having a lower melting temperature, which is the
temperature at which the two different DNA strands come apart. Methylated DNA will have a
higher melting temperature. A dye that changes fluorescence depending on whether the DNA
strands are together or apart can be added
COLD-PCR This technique relies on the same principle as PCR with HRM. In this case only sequences with
low melting temperatures will be amplified. This means that only unmethylated regions will be
amplified
Digestion-based assays This technique also relies on enzymes that cleaves unmethylated DNA at specific sequences, but
methylated DNA is protected
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Abbreviations: COLD: Co-amplification at lower denaturation temperature; DNA: Deoxyribonucleic acid; HRM: high resolution
melting; MLPA: multiplex ligation-dependent probe amplification; MS-MLPA: Methylation-specific multiplex ligation-dependent
probe amplification; MSP: methylation-specific PCR; PCR: polymerase chain reaction.
Table 2. Review question in PICOTS format
Population Patients with diagnosed glioblastoma (at any point after diagnosis) who go onto be treated with temo-
zolomide
Index prognostic factors Tests for MGMT promoter methylation. We will consider each test as a separate prognostic factor
Outcome Overall survival
Timing The outcome is to be predicted at any point after the start of treatment
Setting To give prognostic information before the start of treatment with temozolomide
Abbreviations: MGMT: O6-methylguanine-DNAmethyltransferase; PICOTS: Population, Index prognostic factor, Comparator prog-
nostic factor(s), Outcome, Timing, Setting.
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. glioma/ or astrocytoma/ or glioblastoma/
2. (glioblastom* or GBM or astrocytom* or gliosarcom*).mp.
3. 1 or 2
4. “O(6)-Methylguanine-DNA Methyltransferase”/
5. ((methylguanin* or methyl guanin* or alkylguanin* or alkyl guanin*) adj5 (methyltransferas* or methyl transferas* or alkyltransferas*
or alkyl transferas* or transmethylas* or trans methylas*)).mp.
6. (methyl* DNA protein cystein* adj (methyltransferas* or methyl transferas*)).mp.
7. (AGT or MGMT or AGAT).ti,ab,kf,ot.
8. or/4-7
9. exp Prognosis/
10. (prognos* or predict*).mp.
11. exp mortality/
12. survival/
13. survival rate/
14. exp survival analysis/
15. (mortality or death* or surviv*).mp.
16. Follow-Up Studies/
17. ((followup or follow-up) adj (study or studies)).ti,ab,kf.
18. or/9-17
19. 3 and 8 and 18
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20. exp animals/ not humans.sh.
21. 19 not 20
Appendix 2. BIOSIS Citation Index search strategy
#1 ((TS=((glioblastoma* OR GBM* OR astrocytom*) NEAR (methylguanin* OR “methyl guanin*” OR alkylguanin* OR “alkyl
guanin*” OR AGT OR MGMT OR AGAT)) OR TS=((gliosarcom*) AND (methylguanin* OR “methyl guanin*” OR alkylguanin*
OR “alkyl guanin*” OR AGT OR MGMT OR AGAT))) AND (TS=(prognos* or predict* or mortalit* or death* or surviv*)))
#2 TS=((prognos* OR predict* OR mortalit* OR death* OR surviv*) NEAR (methylguanin* OR “methyl guanin*” OR alkylguanin*
OR “alkyl guanin*” OR AGT OR MGMT OR AGAT)) AND TS=(glioblastom* OR GBM* OR astrocytom* OR gliosarcom*)
#3 ((TS=((prognos OR predict* OR mortalit* OR death* OR surviv*) NEAR (glioblastom* OR GBM* OR astrocytom*)) OR TS=
((prognos OR predict* OR mortalit* OR death* OR surviv*) AND gliosarcom*)) AND (TS=(“O(6)-Methylguanine-DNA Methyl-
transferase” OR “O-6-Methylguanine-DNA Methyltransferase” or “methylated DNA protein cysteine methyltransferase” OR AGT or
MGMT or AGAT) OR TS=((methylguanin* or “methyl guanin*” or alkylguanin* or “alkyl guanin*”) NEAR (methyltransferas* or
“methyl transferas*” or alkyltransferas* or “alkyl transferas*” or transmethylas* or “trans methylas*”))))
#4 (TS=(glioblastom* or GBM or astrocytom* or gliosarcom*) AND (TS=(“O(6)-Methylguanine-DNA Methyltransferase” or “O-
6-Methylguanine-DNA Methyltransferase” or “methylated DNA protein cysteine methyltransferase” or AGT or MGMT or AGAT)
OR TS=((methylguanin* or “methyl guanin*” or alkylguanin* or “alkyl guanin*”) NEAR (methyltransferas* or “methyl transferas*” or
alkyltransferas* or “alkyl transferas*” or transmethylas* or “trans methylas*”))) AND (TS=(prognos* or predict* or mortality or death
or deaths or surviv*)) AND (TS= methylat* OR TS=((amount or amounts or express* or level or levels or activ* or status) NEAR
(protein* or AGT or MGMT or AGAT or methylguanin* or “methyl guanin*” or alkylguanin* or “alkyl guanin*”))))
#5 (#4 or #3 or #2 or #1)
Appendix 3. Risk of bias and applicability assessment
Bespoke tool to assess risk of bias and applicability of prognostic factor studies. SQ = Signalling Question.
Domain 1: Participant selection
Risk of bias SQ1: Was a consecutive or random sample of people enrolled?
SQ2: Was a case-control or cross-sectional design avoided?
SQ3: Did the study avoid inappropriate exclusions?
SQ4: Were all participants included in the analysis?
If no to SQ4: SQ5 Were there important differences between participants who completed the
study/were included in the analysis and those who were not?
Applicability Are there concerns that the included participants and setting do not match the review question?
Domain 2: Prognostic factor measurement
Risk of bias SQ1: Was the method and setting of measurement of the prognostic factor the same for all
participants?
SQ2: Was the prognostic factor objective or measured without knowledge of the outcome or
risk of the outcome?
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(Continued)
SQ3: If a threshold was used, was it pre-specified?
Applicability Are there concerns that prognostic factor, the way that it was measured, or the way that it was
interpreted, differ from the review question?
Domain 3: Outcome measurement
Risk of bias SQ1: Was the method of outcome measurement used adequately valid and reliable?
SQ2: Was the method and setting of outcome measurement the same for all study participants?
SQ3: Was the outcome objective or assessed without knowledge of the prognostic factor?
SQ4: Do the prognostic factors investigated form part of the outcome?
Applicability Are there concerns that outcome does not match the question and/or that follow-up was not of
sufficient duration?
Domain 4: Subsequent treatment
Risk of bias SQ1: Did treatment vary across participants? (or “Was treatment either standardized or random-
ized?”)
Applicability Are there concerns that treatments received do not match the review question?
Domain 5: Adjustment for other potential prognostic factors (where relevant)
Risk of bias Were other potential prognostic factors measured adequately and reliably and in a similar manner
for all participants, and is the method of adding them to the model appropriate?
Applicability Did the prognostic factors adjusted for match the review question?
Domain 6: Selective reporting
Risk of bias Is the reported estimate likely to be selected on the basis of the results from: multiple outcome
measurements, multiple analyses of the prognostic factor-outcome relationship, and/or from
different subgroups?
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Appendix 4. Domains to be considered when judging the strength of the body of evidence
We will consider the following domains when we assess the strength of the body of evidence, based on the GRADE approach (Guyatt
2008).
Domain Explanation
Risk of bias Based on results of ‘Risk of bias’ assessments, we will downgrade confidence in the evidence base if most evidence
is from studies that we judge to be at high risk of bias
Indirectness We will downgrade confidence in the evidence base if we have concerns that the study sample, the prognostic
factor, the outcome, and/or the other factors in themodels in the primary studies do not reflect the review question
Inconsistency We will downgrade confidence in the evidence base if there is unexplained heterogeneity or variability in results
across studies
Imprecision We will downgrade confidence in the evidence base if the estimate of the effect size from a meta-analysis is not
precise or, if no meta-analysis is performed, if the estimate of the size of effect from individual studies is not precise
Publication bias Studies showing no association are likely to be unpublished, unless part of a larger study that specifically aimed
to compare tests. We will downgrade our confidence in the evidence base if we have reason to suspect publication
bias from our assessments of reporting bias
Size of effect We will upgrade our confidence in the evidence base if the size of effect is moderate or large. If a meta-analysis is
not possible, we will upgrade if the size of effect is moderate or large for most included studies
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